🇺🇸 Bevacizumab-awwb in United States
23 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 23
Most-reported reactions
- Chest Discomfort — 4 reports (17.39%)
- Headache — 3 reports (13.04%)
- Chest Pain — 2 reports (8.7%)
- Death — 2 reports (8.7%)
- Flushing — 2 reports (8.7%)
- Infusion Related Reaction — 2 reports (8.7%)
- Nausea — 2 reports (8.7%)
- No Adverse Event — 2 reports (8.7%)
- Pain — 2 reports (8.7%)
- Rash — 2 reports (8.7%)
Other Oncology approved in United States
Frequently asked questions
Is Bevacizumab-awwb approved in United States?
Bevacizumab-awwb does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Bevacizumab-awwb in United States?
Amgen is the originator. The local marketing authorisation holder may differ — check the official source linked above.